		тотп арргочес от то	0920-097					
Patient ID:		Specimen ID:						
- CLOSTRIDIUM DIFFICILE INFECTION (CDI) SURVEILLANCE EMERGING INFECTIONS PROGRAM CASE REPORT FORM -								
Patient's Name:	EILLANCE EMER	Phone No.: ()						
(Last, First, M.I.)								
Address:(Number, Street, Apt. No.)		Chart Number:						
(City) (State)		Hospital:(Zip Code)						
Patient identifie		is NOT transmitted to CDC –						
HEALTH and HUMAN SERVICES CENTERS CLOST PLOUM DUTILGUE INTERCTION (CDI) SURVEIU ANCE								
FOR DISEASE CONTROL AND PREVENTION ATLANTA, GA 30333 EMERGING INFECTIONS PROGRAM CASE REPORT								
1. STATE: 2. COUNTY: 3. STATE ID		4a. LAB/HOSPITAL WHERE 4b. PROVIDER ID	WHERE					
(Residence of Patient) (Residence of Patient)		TOXIN ASSAY PERFORMED: PATIENT TREATE						
	ш	<u> </u>						
5. DATE OF BIRTH: 6. AGE: 7a. SEX: 7b. ETHN	NIC ORIGIN:	7c. RACE: (Check all that apply) 1 □ Native Hawai	ian or					
	oanic or Latino Hispanic or La		Islander					
2 Female 7 Unki		1 □ Black or African American 1 □ Unknown						
8a. DATE OF INCIDENT STOOL 8b. Positive diagnostic assay for	or C. diff:	8c. Location of stool collection: (Check one)						
COLLECTION POSITIVE FOR C. diff: (Check all that apply)		1 ☐ Hospital Inpatient 4 ☐ Long Term Care/ 7 ☐ Unknown	own					
Mo. Dav Year	1 □ NAAT	Facility ID Skilled Nursing 2 □ Long Term Acute Care Facility 8 □ Obser	vation					
1 Culture 1 Cytotoxin	1 🗆 Unknow	wn Hospital Facility ID Unit/0 Facility ID 5 □ Outpatient						
☐☐ Other (specify):		· ·						
		3 ☐ Emergency Room 6 ☐ Other (specify):						
stool collection?		he patient a resident 4 days prior to stool collection? (Check one)						
1 ☐ Yes 2 ☐ No 7 ☐ Unknown	☐ Hospital Inpa	patient 4 □ Long Term Care/ Skilled 6 □ Incarce Nursing Facility 7 □ Unkno						
If YES, Date of Admission: Mo. Day Year	•	Acute Care Hospital Facility ID 8 Other						
		—————————————————————————————————————	specify).					
3 🗆	Home							
11. HCFO classification questions:	12	2. Was CDI a primary or contributing reason for patient's admission?						
a. Was stool collected ≥ 4 days after hospital admission?		1 \(\text{Yes} \) 2 \(\text{No} \) 3 \(\text{Not Admitted} \) 7 \(\text{Unknown} \)						
1 \square Yes (HCFO) 2 \square No (go to 11b.)	<u> </u>	13. Were other enteric pathogens detected from stool at the same date						
b. If no, was stool collected at LTCF/SNF/LTACH?		cident <i>C. diff</i> + stool was collected?						
1 ☐ Yes (HCFO) 2 ☐ No (go to 11c.)		\square Campylobacter 5 \square None 8 \square Other (s	ecify):					
c. If no, was the patient admitted from LTCF/SNF or another acute care set 1 Yes (HCFO) 2 No (CO – complete CRF)	·	2 □ Salmonella 6 □ No other pathogens tested						
Facility ID		3 ☐ Shiga Toxin-Producing <i>E. coli</i> 9 ☐ Norovirus						
d. If HCFO, was this case selected for full CRF based on sampling frame (1:10)?								
1 ☐ Yes (Complete CRF) 2 ☐ No (STOP data abstraction here!)								
14. Exclusion criteria for CA-CDI: (Check all that apply) □ None □ Unk		5. Exposures to healthcare:						
1 ☐ Hospitalized (overnight) at any time in the 12 weeks prior to stool collection date. If yes, Date of most recent discharge:		a. Chronic Hemodialysis prior to incident <i>C. diff</i> + stool:						
Mo. Day Year		1 ☐ Yes 2 ☐ No 7 ☐ Unknown b. Surgical procedure in the 12 weeks prior to incident <i>C. diff</i> + sto	ol.					
□ Unknown		1 ☐ Yes 2 ☐ No 7 ☐ Unknown	OI.					
Facility ID		c. ER visits in the 12 weeks prior to incident <i>C. diff</i> + stool:						
1 Overnight stay in LTACH at any time in the 12 weeks prior to stool collection date		1 □ Yes 2 □ No 7 □ Unknown						
Facility ID 1 □ Residence in LTCF/SNF at any time in the 12 weeks prior to stool collection date Facility ID		d. Observation/CDU stay in the 12 weeks prior to incident <i>C.diff</i> + stool: 1 □ Yes 2 □ No 7 □ Unknown						
16. Patient outcome: 7 □ Unknown								
1 ☐ Survived		2 □ Died						
Date of Discharge: Mo. Day Year		Date of Death: Mo. Day Yo	ear					
			Ш					
If survived, patient was discharged to: 2 □ Long Term Acute Care Hospital 4 □ Long Term Care/ Sk	killed Nursina	a Facility 7 □ Unknown						
Facility ID Facility ID		, ,						
3 □ Home 5 □ Other								

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).

17a. Colectomy (related to CDI):	17b. ICU Admissio	17c. Any additional positive stool test for C. diff ≥ 2 and ≤ 8								
1 ☐ Yes 2 ☐ No 7 ☐ Unknown	stool collectio	1	weeks after the last <i>C. diff</i> + stool specimen? 1 □ Yes 2 □ No							
If YES, Date of Procedure	1 □ Yes 2 □ N									
Mo. Day Year	If YES, Date of ICU Admission Mo. Day Year				If YES, Date of first recurrent specimen Mo. Day Year					
		☐ ☐ ☐ ☐ Unknown								
		T								
18. RADIOGRAPHIC FINDINGS (within 7 days before or after incident <i>C. diff</i> + stool): 19. Was pseudomembranous colitis listed in the surgical pathology, endoscopy, or autopsy report before or after incident <i>C. diff</i> + stool):										
1 ☐ Toxic megacolon 4 ☐ Both		stool)?	•							
2 ☐ Ileus 5 ☐ Not Don				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1 \(\text{Yes} \) 2 \(\text{No} \) 3 \(\text{Not Done} \)					
3 □ Neither 7 □ Information not available 2 □ No 7 □ Information not			available							
20.2 CLINICAL FINDINGS (within 7 days before and up to 1 day after incident C. diff + stool): b. White blood cell count ≤ 1,000/μl:										
d. Diarrhea: e. Upper GI Symptoms: 1 Yes 2 No 3 Not Done										
1 \square Diarrhea by definition (unformed or watery stool, ≥ 3/day for ≥ 1 day) 1 \square Nausea					7 ☐ Information not available					
2 □ Diarrhea documented, but unable to determine if it is by definition 2 □ Vomiting					c. White blood cell count ≥ 15,000/μl:					
3 ☐ No Diarrhea documented 3 ☐ Neither					ı		□ Not Done			
4 — "Asymptomatic" documented in med	lical record		□ Both	مامام	l					
7 ☐ Information not available 7 ☐ Information not available 7 ☐ Information not available										
21. UNDERLYING CONDITIONS: (Check all that apply) If none or no chart available, check appropriate box 1 □ None 1 □ Unknown 1 □ AIDS 1 □ Connective Tissue Disease 1 □ Inflammatory Bowel Disease 1 □ Stem Cell Transplant										
1 AIDS			•				•			
1 Chronic Cognitive Deficit	1 ☐ CVA/Stroke		I ☐ Myocardial Infarct				mor (non metastatic)			
1 ☐ Chronic Kidney Disease 1 ☐ Chronic Liver Disease	1 □ Dementia 1 □ Diabetes		1 □ Peptic Ulcer Diseas 1 □ Peripheral Vascula				logic Malignancy tic Solid Tumor			
1 ☐ Chronic Elver Disease 1 ☐ Chronic Pulmonary Disease	1 ☐ Diabetes 1 ☐ Diverticular D		i □ Peripheral vascula 1 □ Primary Immunod			□ Metasta	tic solia fullioi			
1 ☐ Congenital Heart Disease	1 ☐ Diverticular D		1 \square Short Gut Syndron							
1 ☐ Congestive Heart Failure	1 □ HIV	, ,	i □ Silort Gut Syndron 1 □ Solid Organ Transp							
										
22. Was ICD-9 008.45 or ICD-10 A04.7 listo	-	je form?	23. At time of incid		•		7 🗆 Halmanua			
1 ☐ Yes 2 ☐ No 3 ☐ Not Admitted			1 🗆 Pregnant				/ □ UNKNOWN			
If YES, what was the POA code assigned to			Delivery Date:	Mo.	Day	Year	_			
1 ☐ Y,Yes 3 ☐ U, Unknown	5 🗆 Missing	•								
2 🗆 N, No 4 🗆 W, Clinically Undeterm	ined 6 □ Not Ap	plicable								
24. MEDICATIONSTAKEN 12 WEEKS PRIOR TO		DLLECTION DATE (includ	ling current hospital stay if	collection dat	e > admission o	late):				
(If none or no chart available, check app	ropriate box)									
a. Proton pump inhibitor		1 □ Yes	2 🗆	No		7 🗆 Unkno	own			
(e.g. Esomeprazole, Omeprazole, Lansor	orazole, Pantoprazo	le, Rabeprazole)								
b. H2 Blockers (e.g. Famotidine, Ranitid	line, Cimetidine)	1 ☐ Yes	2 🗆	No	lo 7 □ Unknown					
c. Immunosuppressive therapy (Check	k all that apply)		1 □	None		1 🗆 Unkno	own			
1 ☐ Steroids 1 ☐ Chemotherapy		r agents (specify):	. —			. —				
l '´										
d. Antimicrobial therapy (Check all the			me unknown 1 🗆			1 🗆 Unkno				
			, ,				racycline			
							igecycline 			
	•	•		Nitrofuranto	oin	1 🗆 Tobrai	mycın thoprim -Sulfamethoxazole			
'				D ! -: !!!!						
I I Amp/sulb I I				Penicillin	.		•			
I	Cefoxitin 1	☐ Clarithromycin 1	☐ Levofloxacin 1 ☐	Piperacillin-	Tazobactam	1 ☐ Vanco	mycin (IV)			
1 ☐ Azithromycin 1 ☐	Cefoxitin 1 Cefpodoxime 1	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐	☐ Levofloxacin 1☐☐ Linezolid 1☐	Piperacillin- Rifampin	Tazobactam		mycin (IV)			
1 □ Azithromycin 1 □ 1 □ Aztreonam 1 □	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1	☐ Clarithromycin	□ Levofloxacin 1 □ □ Linezolid 1 □ □ Meropenem 1 □	Piperacillin-	Tazobactam	1 ☐ Vanco	mycin (IV)			
1 ☐ Azithromycin 1 ☐	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 spected or confirm	☐ Clarithromycin	□ Levofloxacin 1 □ □ Linezolid 1 □ □ Meropenem 1 □	Piperacillin- Rifampin	Tazobactam	1 ☐ Vanco	mycin (IV)			
1 □ Azithromycin 1 □ 1 □ Aztreonam 1 □ e. Was patient treated for previous statement 1 □ Yes 2 □	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 Ispected or confirm No 7	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐ ☐ Daptomycin 1 ☐ Med CDI in the prior 1 ☐ Unknown	☐ Levofloxacin 1☐ ☐ Linezolid 1☐ ☐ Meropenem 1☐ ☐ 12 weeks?	Piperacillin- Rifampin	Tazobactam	1 ☐ Vanco	mycin (IV)			
1 ☐ Azithromycin 1 ☐ 1 ☐ Aztreonam 1 ☐ e. Was patient treated for previous st 1 ☐ Yes 2 ☐ If YES, which medication was taken (che	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 ISPECTED TO	☐ Clarithromycin 1	☐ Levofloxacin 1☐☐☐ Linezolid 1☐☐☐ Meropenem 1☐☐☐☐ Meropenem 1☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐	Piperacillin- Rifampin	Tazobactam	1 □ Vanco 1 □ Other	mycin (IV) (specify):			
1 ☐ Azithromycin 1 ☐ 1 ☐ Aztreonam 1 ☐ e. Was patient treated for previous st 1 ☐ Yes 2 ☐ If YES, which medication was taken (che	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 ISPECTED TO	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Unknown unknown if applicable ☐ Fidaxomicin	☐ Levofloxacin 1☐☐☐ Linezolid 1☐☐☐☐ Meropenem 1☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐	Piperacillin- Rifampin Rifaximin	Tazobactam	1 □ Vanco	mycin (IV) (specify):			
1 Azithromycin 1 1 1 1 1 1 1 1 1 1 1 1 1	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 ISPECTED 7 Ceftazidime 7 Ceftazidime 7 Ceftazidime 1 Ceftazi	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Med CDI in the prior 1 ☐ Unknown if applicable ☐ Fidaxomicin — SURVEILLANCE	☐ Levofloxacin 1 ☐ ☐ Linezolid 1 ☐ ☐ Meropenem 1 ☐ 12 weeks? 2): 1 ☐ Other, specify: ☐ OFFICE USE ONLY -	Piperacillin- Rifampin Rifaximin	_	1 □ Vanco 1 □ Other 1 □ Unk	mycin (IV) (specify):			
1 Azithromycin 1 1 1 1 1 Aztreonam 1 1 1 1 1 1 1 1 1 1 1 1 1	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 ISPECTED 7 Ceftazidime 7 Ceftazidime 7 Ceftazidime 1 Ceftazi	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Unknown unknown if applicable ☐ Fidaxomicin	☐ Levofloxacin 1 ☐ ☐ Linezolid 1 ☐ ☐ Meropenem 1 ☐ 12 weeks? 2): 1 ☐ Other, specify: ☐ OFFICE USE ONLY -	Piperacillin- Rifampin Rifaximin	Tazobactam 27. Initials	1 □ Vanco 1 □ Other 1 □ Unk	mycin (IV) (specify): nown 29. Identified through			
1 Azithromycin 1 1 1 1 1 Aztreonam 1 1 1 1 1 1 1 1 1 1 1 1 1	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 ISPECTED 7 Ceftazidime 7 Ceftazidime 7 Ceftazidime 1 Ceftazi	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Unknown ☐ Fidaxomicin — SURVEILLANCE ☐ Que CDI episode (>8 €	☐ Levofloxacin 1 ☐ ☐ Linezolid 1 ☐ ☐ Meropenem 1 ☐ 12 weeks? 2): 1 ☐ Other, specify: ☐ OFFICE USE ONLY -	Piperacillin- Rifampin Rifaximin	_	1 □ Vanco 1 □ Other 1 □ Unk	mycin (IV) (specify): nown 29. Identified through audit			
1 Azithromycin 1 1 1 1 1 Aztreonam 1 1 1 1 1 1 1 1 1 1 1 1 1	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 Ispected or confirm No 7 ck all that apply, or Vancomycin 1 26. Previous union	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Unknown If applicable ☐ Fidaxomicin — SURVEILLANCE que CDI episode (>8 € O	☐ Levofloxacin 1 ☐ ☐ Linezolid 1 ☐ ☐ Meropenem 1 ☐ 12 weeks? 2): 1 ☐ Other, specify: ☐ OFFICE USE ONLY -	Piperacillin- Rifampin Rifaximin	_	1 □ Vanco 1 □ Other 1 □ Unk	mycin (IV) (specify): nown 29. Identified through			
1	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 Ispected or confirm No 7 ck all that apply, or Vancomycin 1 26. Previous unio 1 □ Yes 2 □ No	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Unknown If applicable ☐ Fidaxomicin — SURVEILLANCE que CDI episode (>8 € O	☐ Levofloxacin 1 ☐ ☐ Linezolid 1 ☐ ☐ Meropenem 1 ☐ 12 weeks? 2): 1 ☐ Other, specify: ☐ OFFICE USE ONLY -	Piperacillin- Rifampin Rifaximin	_	1 □ Vanco 1 □ Other 1 □ Unk	mycin (IV) (specify): nown 29. Identified through audit			
1 Azithromycin 1 1 1 1	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 Ispected or confirm No 7 ck all that apply, or Vancomycin 1 26. Previous unio 1 □ Yes 2 □ No	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Unknown If applicable ☐ Fidaxomicin — SURVEILLANCE que CDI episode (>8 € O	☐ Levofloxacin 1 ☐ ☐ Linezolid 1 ☐ ☐ Meropenem 1 ☐ 12 weeks? 2): 1 ☐ Other, specify: ☐ OFFICE USE ONLY -	Piperacillin- Rifampin Rifaximin	_	1 □ Vanco 1 □ Other 1 □ Unk	mycin (IV) (specify): nown 29. Identified through audit			
1	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 Ispected or confirm No 7 ck all that apply, or Vancomycin 1 26. Previous unio 1 □ Yes 2 □ No	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Unknown If applicable ☐ Fidaxomicin — SURVEILLANCE que CDI episode (>8 € O	☐ Levofloxacin 1 ☐ ☐ Linezolid 1 ☐ ☐ Meropenem 1 ☐ 12 weeks? 2): 1 ☐ Other, specify: ☐ OFFICE USE ONLY -	Piperacillin- Rifampin Rifaximin	_	1 □ Vanco 1 □ Other 1 □ Unk	mycin (IV) (specify): nown 29. Identified through audit			
1	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 Ispected or confirm No 7 ck all that apply, or Vancomycin 1 26. Previous unio 1 □ Yes 2 □ No	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Unknown If applicable ☐ Fidaxomicin — SURVEILLANCE que CDI episode (>8 € O	☐ Levofloxacin 1 ☐ ☐ Linezolid 1 ☐ ☐ Meropenem 1 ☐ 12 weeks? 2): 1 ☐ Other, specify: ☐ OFFICE USE ONLY -	Piperacillin- Rifampin Rifaximin	_	1 □ Vanco 1 □ Other 1 □ Unk	mycin (IV) (specify): nown 29. Identified through audit			
1	Cefoxitin 1 Cefpodoxime 1 Ceftazidime 1 Ispected or confirm No 7 ck all that apply, or Vancomycin 1 26. Previous unio 1 □ Yes 2 □ No	☐ Clarithromycin 1 ☐ Clindamycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Daptomycin 1 ☐ Unknown If applicable ☐ Fidaxomicin — SURVEILLANCE que CDI episode (>8 € O	☐ Levofloxacin 1 ☐ ☐ Linezolid 1 ☐ ☐ Meropenem 1 ☐ 12 weeks? 2): 1 ☐ Other, specify: ☐ OFFICE USE ONLY -	Piperacillin- Rifampin Rifaximin	_	1 □ Vanco 1 □ Other 1 □ Unk	mycin (IV) (specify): nown 29. Identified through audit			